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responsibility of XAbstract A rapid selective method for the analysis of ﬂunarizine and its associated impurities was
developed and validated according to ICH guidelines. The separation was carried out using a Thermo
Scientiﬁc Hypersil Gold C18 column (50 mm 4.6 mm i.d., 1.9 mm particle size) with a gradient
mobile phase of acetonitrile–ammonium acetate–tetrabutylammoniumhydrogen sulfate buffer, at a
ﬂow rate of 1.8 mL/min and UV detection at 230 nm. Naturally aged samples were also tested to
determine sample stability. A proﬁle of sample and impurity breakdown was also presented.
& 2013 Xi’an Jiaotong University. Production and hosting by Elsevier B.V. All rights reserved.1. Introduction
Flunarizine, 1-[bis(4-ﬂuorophenyl)methyl]-4-[(2E)-3-phenylprop-2-
en-1-yl] piperazine (Fig. 1), is a piperazine derivative produced by
Janssen Pharmaceuticals Ltd. It is a mixed T and L type calcium
channel blocker and sodium channel antagonist, so it can be used
for the treatment of cardiovascular and neurological diseases, asersity. Production and hosting by E
.005
61 208208x423;
ie (M. Geary).
i’an Jiaotong University.well as in the prophylaxis and treatment of migraine headache. It
is also an anticonvulsant and has been reported to reduce the
duration of recurrent hemiplegia in children [1]. It has a number of
known impurities which are close in structure to the main
compound. The current approved pharmacopoeia HPLC method
for the determination of the main related substances is described in
the European Pharmacopoeia [2]. Other methods for the HPLC
analysis of ﬂunarizine dihydrochloride in tablets have been
detailed in the literature [3].
There are a number of methods described in the literature
discussing the use of spectrophotometric techniques for ﬂunar-
izine determination [4,5] as well as other chromatographic
methods such as GC [6–8]. There are also a range of other
papers describing the HPLC analysis of the compound in a
number of matrices [9–12]. The current work presents a method
that reduces the analysis time for ﬂunarizine and its relatedlsevier B.V. All rights reserved.
NFig. 1 The structure of ﬂunarizine.
N. O’Connor et al.212impurities by almost 60% in comparison to the current approved
European Pharmacopoeia method while still meeting the require-
ments for the validation parameters tested. Furthermore, labora-
tory stability studies indicate that the active pharmaceutical
ingredient (API) and its impurities are stable in solution at
ambient conditions upto 2 weeks after initial preparation.2. Experimental
2.1. Materials and reagents
Samples of ﬂunarizine dihydrochloride active pharmaceutical
ingredient and the related impurities were supplied by Janssen
Pharmaceutical Ltd., Cork, Ireland. HPLC-grade acetonitrile
together with analytical grade ammonium acetate and tetrabu-
tylammoniumhydrogen sulfate (TBAHS) [C16H35N H2SO4],
was purchased from VWR International (an Ireland supplier).
Ultra-pure water was obtained using a Thermoﬁsher TKA water
puriﬁcation system.
2.2. Instrumentation
The system used was an Agilent 1200 Rapid Resolution
Liquid Chromatograph, with a 1200 Series binary pump SL
and vacuum degasser, a 1200 Series high-performance auto-
sampler, a 1200 Series thermostatted column compartment
SL, a 1200 Series DAD SL for up to 80 Hz operation which
was controlled by ChemStation B.02.01.SR1 data acquisition
and evaluation software. The original analysis was carried out
on a Thermo Scientiﬁc BDS C18 column (100 mm 4.6 mm
i.d., 3 mm particle size). The column used for the new method
was a Thermo Scientiﬁc Hypersil Gold C18 column (50 mm
4.6 mm i.d., 1.9 mm particle size).
2.3. Standard solutions and chromatographic conditions
Test solution for tests on original column was prepared by
adding 2 mg of the API and each of the impurities to a 25 mL
volumetric ﬂask and diluting to volume with the mobile phase.
Solution for elution order was prepared by adding 2 mg of
the API (on its own) to a 25 mL volumetric ﬂask and diluting
to volume with the mobile phase. This was repeated for all
impurities A–D.
Linearity solutions for validation of the new method: A stock
solution of 80 mg/L was prepared by weighing 2 mg each of
the API and impurities A–D and adding them to a 25 mLvolumetric ﬂask. These standards were diluted appropriately
for the linearity studies.
The conditions for the original method were as follows:
The Thermo Scientiﬁc BDS C18 column (3 mm, 100 mm 4.6
mm i.d.) was installed in the thermostatted oven compartment
and conditioned before switching to the mobile phase to
equilibrate for 10 min or until a stable baseline was achieved.
The mobile phase consisted of (A) a buffered solution
prepared by dissolving 23.8 g of TBAHS and 7 g of ammo-
nium acetate in 1.0 L of ultra-pure water and (B) acetonitrile.
A gradient elution program was used as follows: 0–12 min,
20–60% B; 12–15 min, 60% B; 15–16 min, 60–20% B; and
16–20 min, 20% B.
The ﬂow rate was 1.5 mL/min with the oven at ambient
temperature; the injection volume was 10 mL with the UV
detector wavelength set at 230 nm.
The conditions for the newly developed method were as
follows: The Thermo Scientiﬁc Hypersil Gold C18 column
(1.9 mm, 50 mm 4.6 mm i.d.) was installed in the thermo-
statted oven compartment and conditioned by passing acet-
ronitrile through it for an hour. The solvent was then switched
to the mobile phase to equilibrate for 10 min or until a stable
baseline was achieved. The gradient for the new method was
as follows: 0–5 min, 25–43% B; 5–5.5 min, 43% B; 5.5–6 min,
43–25% B; and 6–8.5 min, 25% B.
The ﬂow rate was 1.8 mL/min with the oven at ambient
temperature; the injection volume was 5 mL with the UV
detector wavelength set at 230 nm.3. Results and discussion
Flunarizine HCl and its four main impurities were ﬁrst
analyzed with the original method [2], on the Hypersil BDS
C18 3 mm column, where a run time of 20 min was employed
and the last peak, impurity D, was eluted at approximately
8 min (Fig. 2).
3.1. Method development
An extensive investigation into what was the most suitable sub
2 mm column available was conducted. The carbon load and
pore size were examined and compared to the available columns.
A Hypersil Gold 1.9 mm column was available and it had similar
percentage carbon loads as well as the same USP classiﬁcation.
With the newly developed gradient a resolution of 1.6 or
greater for components was obtained and all peaks were eluted
in approximately 4.3 min (Fig. 3).
The original method had a column conditioning step, which
helped prevent buffer precipitation. With regard to the new
method and column, a thorough wash step should be incor-
porated into the end of any sequence where the column will
not be used afterwards for any length of time. This is to clear
any buffer present on the column after analysis and to prevent
precipitation.
3.2. Method validation
3.2.1. Linearity
The method was validated in accordance with the ICH guide-
lines. The linearity was examined over six concentrations, 10–
40 mg/mL. The peak area for the individual replicated together
Fig. 2 Separation of ﬂunarizine and its four main impurities on
the original column.
Fig. 3 Separation of ﬂunarizine and its four main impurities on
Hypersil Gold 1.9 mm column.
Table 1 Linearity data for ﬂunarizine over the concentration ran
Conc. (mg/mL) Absorbance (mAU)
Rep 1 Rep 2 Rep
15 80.5 78.9 78
20 109.9 109.8 110
25 138.3 138.2 137
30 162.7 164.7 164
35 193.2 192.8 191
40 223.3 222.0 223
Table 2 The ranges of relative standard deviations seen for each
Conc. (mg/mL) RSD (%)
Imp A Im
15 0.05 0.5
20 0.36 0.7
25 0.83 0.2
30 2.04 0.4
35 0.09 0.3
40 1.15 0.3
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Linear regression analysis was performed giving a regression
equation of analysis was performed giving a regression equation
of y¼5.66254.5608 and a correlation coefﬁcient of 0.9994.
The relative standard deviation was also calculated and found to
be within speciﬁcation at the percent values between 0.34% and
1.35%.
Calibration curves were also prepared for the four main
impurities. Regression analysis was performed and correlation
coefﬁcient values ranged from 0.9992 to 0.9996. The percent
relative standard deviation was calculated for impurities at
each concentration (Table 2).
The linear relationship was shown with all the correlation
coefﬁcients over 0.99. The percent RSD values were also
within acceptable limits of 1.5% for the API and the accepted
limit of 10% for the impurities. The percent recovery was
calculated for ﬂunarizine and its four main impurities, the
values were between 95% and 105% which was within the
acceptable range for this method.3.2.2. Precision
Precision was assessed with respect to analysis repeatability
and injection repeatability in accordance with Janssens’’
speciﬁc requirements.
Analysis repeatability was performed by injecting six
replicates of a 25 mg/mL and a 35 mg/mL solution of ﬂunar-
izine and impurities. % RSD values were found to range from
0.67% to 1.21% for the 25 mg/mL sample and 0.47% to 0.84%
for the 35 mg/mL sample (Table 3).
Injection repeatability was performed by injecting a solu-
tion of ﬂunarizine and its impurities at two different concen-
trations (15 mg/mL and 30 mg/mL) for six times. % RSD
values ranged from 0.27% to 0.76% for the 15 mg/mL sample
and 0.30% to 0.45% for the 30 mg/mL sample (Table 3).ge 15–40 mg/mL.
SD RSD (%)
3 Mean
.5 79.3 1.1 1.35
.9 79.3 0.6 0.58
.3 110.2 0.5 0.37
.8 137.9 1.2 0.71
.5 164.1 0.9 0.46
.4 192.5 0.8 0.34
impurity from linearity studies.
p B Imp C Imp D
6 0.63 0.92
8 0.33 1.84
5 0.10 1.62
0 0.33 1.58
4 0.50 1.07
8 0.22 0.57
Table 3 RSD (%) data for precision studies for the API and its four impurities.
Compound Injection repeatability (RSD; %) Analysis repeatability (RSD; %)
15 mg/mL 30 mg/mL 25 mg/mL 35 mg/mL
Imp A 0.40 0.36 0.67 0.66
Imp B 0.27 0.32 0.85 0.47
Imp C 0.48 0.30 1.18 0.64
Imp D 0.76 0.30 1.16 0.84
API 0.49 0.45 1.21 0.29
Fig. 4 Sample stability chromatograms for naturally aged
ﬂunarizine and its impurities on day 0 (A) and day 14 (B) for
samples stored in the clear vials under ambient conditions.
N. O’Connor et al.214The results for both types of precision examined were well
within the speciﬁed limits as all had % RSD values of less than
1.5%. Resolution data were obtained by injecting a solution
containing 8 mg/mL of the API and its impurities (n¼6) with
the resolution between all peaks greater than 1.5.
3.2.3. Sample stability
Samples were stored in the clear and amber glassware at
ambient temperatures in the fridge. Their stability was
assessed at three intervals: immediately, after 1 week and 2
weeks, respectively. There was no notable degradation of any
peaks at any of the testing intervals. This means that the
samples can be kept and tested for upto 2 weeks without any
degradation occurring. Data from the stability studies fromnaturally aged samples retained in the clear vials are shown in
Fig. 4.
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